MA49374A - Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine - Google Patents

Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine

Info

Publication number
MA49374A
MA49374A MA049374A MA49374A MA49374A MA 49374 A MA49374 A MA 49374A MA 049374 A MA049374 A MA 049374A MA 49374 A MA49374 A MA 49374A MA 49374 A MA49374 A MA 49374A
Authority
MA
Morocco
Prior art keywords
vanine
inhibitors
compounds used
heteroaromatic compounds
heteroaromatic
Prior art date
Application number
MA049374A
Other languages
English (en)
Inventor
Todd Bosanac
Michael J Burke
Brian Nicholas Cook
Darren Todd Disalvo
Jr Thomas Martin Kirrane
Yue Shen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA49374A publication Critical patent/MA49374A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA049374A 2017-06-12 2018-06-08 Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine MA49374A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762518106P 2017-06-12 2017-06-12

Publications (1)

Publication Number Publication Date
MA49374A true MA49374A (fr) 2021-04-21

Family

ID=62631060

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049374A MA49374A (fr) 2017-06-12 2018-06-08 Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine

Country Status (22)

Country Link
US (2) US10364255B2 (fr)
EP (1) EP3638680B1 (fr)
JP (1) JP6880243B2 (fr)
KR (1) KR102607934B1 (fr)
CN (1) CN110770242B (fr)
AR (1) AR112086A1 (fr)
AU (1) AU2018285131B2 (fr)
CA (1) CA3066946A1 (fr)
CL (1) CL2019003515A1 (fr)
CO (1) CO2019013823A2 (fr)
DK (1) DK3638680T3 (fr)
EA (1) EA039223B1 (fr)
ES (1) ES2927021T3 (fr)
HU (1) HUE060597T2 (fr)
IL (1) IL271104B (fr)
MA (1) MA49374A (fr)
MX (1) MX394645B (fr)
PE (1) PE20200340A1 (fr)
PH (1) PH12019502693A1 (fr)
PL (1) PL3638680T3 (fr)
TW (1) TWI855993B (fr)
WO (1) WO2018228934A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
PE20200340A1 (es) * 2017-06-12 2020-02-14 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de vanina
EP3837263B1 (fr) 2018-08-13 2024-07-03 F. Hoffmann-La Roche AG Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
JOP20210034A1 (ar) * 2018-08-28 2021-02-25 Boehringer Ingelheim Int مركبات عطرية غير متجانسة كمثبطات Vanin
EP3883936B1 (fr) 2018-11-22 2023-07-12 F. Hoffmann-La Roche AG Nouveaux composés hétérocycliques
BR112021007915A2 (pt) 2018-12-03 2021-07-27 Boehringer Ingelheim International Gmbh compostos heteroaromáticos utilizados como inibidores de vanina
JP7080405B2 (ja) 2018-12-03 2022-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング バニン阻害剤としての複素芳香族化合物
EA202191478A1 (ru) 2018-12-03 2021-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Гетероароматические соединения в качестве ингибиторов ванина
US11814375B2 (en) 2019-09-12 2023-11-14 Hoffmann-La Roche Inc. Heterocyclic compounds
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
EP4696293A1 (fr) 2023-04-10 2026-02-18 Umov SPA Système de réhabilitation et de surveillance
CN118892548A (zh) * 2024-08-12 2024-11-05 中国人民解放军陆军特色医学中心 Vanin-1抑制剂在制备治疗急性肾损伤继发急性肺损伤的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004018811D1 (de) * 2003-10-09 2009-02-12 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
EP3303303A1 (fr) * 2015-05-29 2018-04-11 Pfizer Inc Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1
BR112019000589A2 (pt) * 2016-07-14 2019-04-24 Pfizer Inc. pirimidina carboxamidas como inibidores da enzima vanina-1
PE20200340A1 (es) * 2017-06-12 2020-02-14 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de vanina

Also Published As

Publication number Publication date
JP2020522517A (ja) 2020-07-30
AU2018285131A1 (en) 2019-10-31
US10364255B2 (en) 2019-07-30
IL271104B (en) 2022-03-01
CL2019003515A1 (es) 2020-06-19
DK3638680T3 (da) 2022-09-05
TW201920196A (zh) 2019-06-01
AR112086A1 (es) 2019-09-18
CN110770242B (zh) 2022-08-19
PL3638680T3 (pl) 2022-12-19
AU2018285131B2 (en) 2021-11-11
PH12019502693A1 (en) 2020-07-13
JP6880243B2 (ja) 2021-06-02
PE20200340A1 (es) 2020-02-14
TWI855993B (zh) 2024-09-21
WO2018228934A1 (fr) 2018-12-20
HUE060597T2 (hu) 2023-04-28
EP3638680A1 (fr) 2020-04-22
EA202090014A1 (ru) 2020-05-12
CO2019013823A2 (es) 2020-01-17
KR102607934B1 (ko) 2023-12-01
ES2927021T3 (es) 2022-11-02
KR20200013718A (ko) 2020-02-07
CA3066946A1 (fr) 2018-12-20
CN110770242A (zh) 2020-02-07
IL271104A (en) 2020-01-30
MX394645B (es) 2025-03-21
MX2019014876A (es) 2020-02-13
EA039223B1 (ru) 2021-12-20
US20190263828A1 (en) 2019-08-29
US20180354968A1 (en) 2018-12-13
EP3638680B1 (fr) 2022-08-10
BR112019021703A2 (pt) 2020-05-12

Similar Documents

Publication Publication Date Title
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
EP3768661A4 (fr) Composés deutérés utilisés en tant qu'inhibiteurs de rock
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3621624A4 (fr) Composés dinucléotidiques cycliques en tant qu'agonistes sting
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx